Banco Santander S.A. Makes New $809,000 Investment in Exelixis, Inc. (NASDAQ:EXEL)

Banco Santander S.A. acquired a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 24,295 shares of the biotechnology company's stock, valued at approximately $809,000.

Several other institutional investors have also added to or reduced their stakes in the business. Seizert Capital Partners LLC increased its stake in shares of Exelixis by 8.0% in the third quarter. Seizert Capital Partners LLC now owns 469,940 shares of the biotechnology company's stock worth $12,195,000 after acquiring an additional 34,875 shares during the period. Los Angeles Capital Management LLC grew its holdings in Exelixis by 124.0% during the third quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company's stock worth $46,473,000 after acquiring an additional 991,494 shares during the period. Tri Ri Asset Management Corp purchased a new position in Exelixis during the third quarter valued at approximately $4,396,000. CWA Asset Management Group LLC acquired a new position in Exelixis in the third quarter valued at approximately $577,000. Finally, Blue Trust Inc. lifted its holdings in Exelixis by 134.7% in the fourth quarter. Blue Trust Inc. now owns 14,302 shares of the biotechnology company's stock valued at $476,000 after acquiring an additional 8,208 shares during the period. Institutional investors and hedge funds own 85.27% of the company's stock.

Exelixis Price Performance

Shares of EXEL traded down $0.40 during mid-day trading on Thursday, reaching $36.80. The stock had a trading volume of 2,418,356 shares, compared to its average volume of 2,087,266. The business's fifty day moving average is $35.25 and its 200 day moving average is $32.33. Exelixis, Inc. has a 52-week low of $20.14 and a 52-week high of $40.02. The firm has a market cap of $10.30 billion, a price-to-earnings ratio of 20.79, a P/E/G ratio of 1.13 and a beta of 0.57.

Remove Ads

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. As a group, sell-side analysts anticipate that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

EXEL has been the subject of several analyst reports. Wells Fargo & Company cut shares of Exelixis from an "overweight" rating to an "equal weight" rating and set a $36.00 target price for the company. in a research note on Monday, February 24th. Piper Sandler increased their target price on shares of Exelixis from $37.00 to $38.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 12th. JMP Securities restated a "market outperform" rating and issued a $41.00 price target on shares of Exelixis in a research note on Thursday, January 23rd. Stifel Nicolaus increased their price target on Exelixis from $30.00 to $36.00 and gave the stock a "hold" rating in a research report on Wednesday, February 12th. Finally, UBS Group boosted their price objective on Exelixis from $30.00 to $34.00 and gave the company a "neutral" rating in a research report on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $37.59.

Insider Activity at Exelixis

In other news, Director Mary C. Beckerle sold 12,210 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $34.88, for a total value of $425,884.80. Following the completion of the sale, the director now directly owns 30,406 shares of the company's stock, valued at approximately $1,060,561.28. This represents a 28.65 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Christopher J. Senner sold 29,314 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $36.14, for a total value of $1,059,407.96. Following the sale, the chief financial officer now directly owns 779,607 shares of the company's stock, valued at approximately $28,174,996.98. This represents a 3.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 140,343 shares of company stock valued at $5,177,234 over the last 90 days. 2.85% of the stock is owned by corporate insiders.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.